Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
Climb Bio reported positive initial Phase 1 data for CLYM116, its anti-APRIL 'sweeper' antibody in development for IgA nephropathy, highlighting a ~29-day half-life and >90% free APRIL suppression after a single 320 mg dose. The 46-subject trial showed 60-75% IgA, Gd-IgA1, and IgM suppression maintained through 12 weeks, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia, supporting a potential every-12-week dosing regimen with a half-life roughly threefold longer than sibeprenlimab.
Key figures
- Drug Name
- CLYM116
- Phase Of Trial
- Phase 1
- Dosing regimen
- every-12-week (Q12W) potential, supported by PK/PD modeling
- Half life days
- ~29 days
- April suppression
- >90% free APRIL suppression after single 320 mg dose
- Phase3 initiation
- 2027
- Subjects enrolled
- 46
- Navigate2 initial data
- H1 2027
- Iga gd iga1 suppression
- 60-75% maintained through 12 weeks
- Formulation concentration
- 200 mg/mL high-concentration formulation enabling 400 mg single SC injection
- Half life vs sibeprenlimab
- threefold longer
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.